The global multiple unit pellet systems (MUPS) market has been valued at US$ 3.6 billion in the year 2023, expanding at a CAGR of 3.6% to reach US$ 5.2 billion by the end of 2033. According to a recent study, extended-release dosage forms led the market with a share of about 47.1% in 2023.
Granules, pellets, microspheres, microcapsules, and minitablets are examples of MUPS formulations. MUPS formulations are designed to help people swallow capsules more easily and to improve their physicochemical stability in comparison to suspensions. The MUPS formulations have great bioavailability and are very convenient dosage forms. As they are convenient and user-friendly alternatives to regular tablets, MUPS tablets are rapidly gaining traction across the globe.
MUPS tablets and capsules are the most recommended dosage form due to their non-invasiveness, greater patient compliance, and convenience of drug administration. It is used for disease conditions where repeated long-term drug administration is required, such as gastrointestinal and colon drug delivery.
In addition to being convenient and affordable, it is the safest dosage form. This is expected to fuel the growth in the multiple unit pellet systems market over the forecast period. On the back of these aforementioned factors, the sales of multiple unite pellet systems are expected to surge by 1.6x through 2023 & beyond.
| Attributes | Multiple Unit Pellet Systems Market (From 2018 to 2022) |
|---|---|
| CAGR | 2.7% |
| Market Size - 2017 | US$ 3.138 billion |
| Market Size - 2022 | US$ 3.585 billion |
| Attributes | Multiple Unit Pellet Systems Market (From 2023 to 2033) |
|---|---|
| CAGR | 3.6% |
| Market Size - 2023 | US$ 3.6 billion |
| Market Size - 2033 | US$ 5.2 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per Future Market Insights (FMI), the multiple unit pellet systems market accounted for around 20.1% of the overall US$ 17.3 billion oral controlled release drug market in 2022. The sales of multiple unit pellet systems expanded at a CAGR of 2.6% from 2018 to 2022, owing to the rise in the use of pellets in drug formulations.
Due to their intrinsic benefits, such as the flexibility they provide when compared with conventional forms, and their ability to provide modified release, immediate release, great therapeutic, and taste-masked formulations, MUPS formulations may continue to gain adoption over traditional drug delivery systems (DDS).
In addition to being manufactured in encapsulated pill, or sachet formats, MUPS assist patients in swallowing drugs more easily, a characteristic that is becoming more crucial in targeted medications for pediatric and geriatric populations.
By incorporating taste and odor masking, numerous dose ranges, and the convenience of administration, MUPS makes complex medications reduces the challenge. Backed by this, the multiple unit pellet systems market is anticipated to record a CAGR of 3.5% during the forecast period.
Increasing the use of pellets in drug formulations is expected to create tremendous opportunities in the MUPS market. Due to the numerous benefits pellets offer to both manufacturers and patients, the use of pellets in drug formulations has gained popularity, boosting the demand for multiple unit pellet system (MUPS) formulations.
Pellets are small, spherical, free-flowing particulates with a variety of skills, one of which is the capacity to create MUPS formulations and multi-drug blends, which is a significant advantage.
Pellets have many benefits for production, from flexibility in combining active compounds into oral dosage forms to the product's overall appearance. Pellets provide a variety of release mechanisms, including sustained, gastro-resistant, and controlled release.
Principal Consultant
One of the key factors affecting sales negatively is the complex and challenging production process for MUPS tablets. Manufacturing MUPS tablets involves multiple challenges, including particle segregation during compression and compression forces that could harm the functional coating. Understanding the variables influencing coat damage during pellet compression and segregation during tablet manufacturing is essential.
The fragmentation of pellets during compaction into MUPS tablets is another factor limiting the multiple unit pellet systems market growth. The quality of MUPS tablets may be impacted by the excipients used, as well as homogeneous blends of excipients and pellets. Key players are likely to face challenges while developing MUPS formulations due to the factors mentioned above.
| Category | Formulation |
|---|---|
| Leading Segment | Extended Release Dosage Form |
| Market Share | 47.23% |
| Category | Dosage Form |
|---|---|
| Leading Segment | Capsules |
| Market Share | 47.31% |
Capsules to Remain Highly Sought-after Dosage Form in MUPS Market
Regarding formulation, the extended-release dosage form held the leading market share of about 47.23% in the global market in 2023 and is expected to record a CAGR of 3.5% over the forecast period. As extended-release MUPS tablets are largely used in healthcare institutions, growth in the segment is expected to surge.
While based on dosage form, the capsules segment held a revenue share of 41.3% in 2023 and is poised to expand at a CAGR of 3.3% between 2023 and 2033. Capsules are the most preferred dosage form for MUPS due to advantages such as non-invasiveness and patient compliance. Apart from that, the convenience of drug administration is also considered a significant factor pushing the demand for capsules.
Nearly 69% of Multiple Unit Pellet Systems Sales Come from Proton Pump Inhibitors.
Based on the drug class, the proton pump inhibitors segment held a revenue share of 67.9% in 2023, as MUPS of proton pump inhibitors is largely accepted and available across the globe. Based on distribution channels, hospital pharmacies are expected to be the most preferable distribution channel to access the drug class.
As per FMI, the segment held a significant market share value of 32.9% in 2023 and is expected to account for US$ 1,595.9 million in revenues in 2033 in the MUPS market due to many patient footfalls in hospitals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Countries | Global Market Share - 2033 |
|---|---|
| North America | 29.6% |
| Europe | 25.9% |
Over 9 out of 10 Multiple Unit Pellet Systems Market Sales in North America to be Account by the United States
The United States dominated North American multiple unit pellet systems market with a total demand share of 91.3% in 2023. Growth in the United States market is expected to surge throughout the forecast period owing to the rising prevalence of gastrointestinal disease and growing demand for gastro-resistant drugs.
As per FMI, the United States is expected to spearhead the growth, with sales expected to increase at a steady pace through 2023 & beyond. Demand for MUPS in the United States is expected to rise at 3.2% CAGR, with the country attributing over 91.9% of total sales in the North American market. The United States MUPS market is expected to reach US$ 1,325.7 million by the end of 2033.
Increasing Research & Development Activities for Efficient Dosage to Push Sales
FMI estimates India held around 48.5% share in South Asia's multiple unit pellet systems market in 2023 and may display a growth rate of 5.4% between 2023 and 2033. With the need for advanced medicine, India's pharmaceutical manufacturers are increasing research and development spending.
The development of efficient dosage forms of already-approved medications, including MUPS formulations, is facilitated by an increase in the research and development of innovative DDS. By increasing patient compliance, MUPS of PPI, for instance, may enhance the demand for MUPS formulations in India.
On the back of these factors, the demand for multiple unit pellet systems in India is expected to accelerate at 5.4% CAGR during the forecast period. India is expected to spearhead the growth in the South Asia market, contributing over 52% of revenue in 2033.
| Countries | Global Market CAGR (From 2023 to 2033) |
|---|---|
| Australia | 1.8% |
| China | 4.4% |
| India | 5.5% |
| United Kingdom | 3.9% |
Favorable Reimbursement Policies in China to Augment Multiple Unit Pellet Systems Demand
China is set to exhibit a CAGR of nearly 4.3% in the East Asia multiple unit pellet systems market during the forecast period. Due to its efficient drug production, China offers medicines at incredibly affordable costs. The prices of top pharmaceutical brands have decreased by an average of 61% in China due to the updated reimbursement policies.
For instance, it has been claimed that pharmaceutical giants Roche and Novartis have agreed to lower the cost of several of their most recent medications in China. This is expected to aid the growth in China market and improve the sales of novel and potent drug formulations, including MUPS tablets and capsules.
According to the study, Germany held around 20.1% share in the Europe MUPS market in 2023 and is projected to display a growth of 4.1% during the forecast period. Consolidation of the pharmaceutical industry in the European countries, including Germany, combined with expansion in outsourcing for MUPS manufacturing, is boosting the multiple unit pellet systems market.
FMI estimates Germany may account for nearly 22% of the demand share in the Europe market, with sales in the country topping a valuation of US$ 279.9 million in 2033. The United Kingdom. It is expected to be the second-leading market in Europe, accounting for around 18.2% of revenue in Europe.
| Countries | Global Market Share (2023) |
|---|---|
| United States | 27.0% |
| Germany | 5.2% |
| Japan | 5.6% |
One of the key factors influencing the rise in the acceptance of multiple unit pellet system (MUPS) formulations is the growth in FDA approvals for pharmaceuticals in the United States. The leading multiple unit pellet system manufacturers are focusing on getting fast-track drug approvals to expand their product portfolio and strengthen their position in the industry.
Recent Developments
The market size of multiple unit pellet systems is to hit US$ 5.2 billion by 2033.
The multiple unit pellet system industry is to record a valuation of US$ 3.6 billion in 2023.
The multiple unit pellet system industry is likely to secure a CAGR of 3.6% through 2033.
The key players in the global multiple unit pellet systems market are AstraZeneca plc, Merck KGaA, Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Galderma SA, and Novartis AG.
Players opt for mergers and acquisitions.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Formulation 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Formulation, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Formulation, 2023 to 2033 5.3.1. Extended Release Dosage Form 5.3.2. Delayed Release Dosage Form 5.3.3. Delayed Release Orodispersible Dosage Form 5.3.4. Others 5.4. Y-o-Y Growth Trend Analysis By Formulation, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Formulation, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Form 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Dosage Form, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033 6.3.1. Tablets 6.3.2. Capsules 6.3.3. Sachets 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Dosage Form, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Drug Class , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class , 2023 to 2033 7.3.1. Anti-Hypertensive 7.3.2. Proton Pump Inhibitors 7.3.3. Antibiotics 7.3.4. Analgesics 7.3.5. Others 7.4. Y-o-Y Growth Trend Analysis By Drug Class , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Drug Class , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Drug Stores 8.3.4. Online Pharmacies 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. South Asia and Pacific 9.3.6. East Asia 9.3.7. Middle East and Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA. 10.2.1.2. Canada 10.2.2. By Formulation 10.2.3. By Dosage Form 10.2.4. By Drug Class 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Formulation 10.3.3. By Dosage Form 10.3.4. By Drug Class 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Formulation 11.2.3. By Dosage Form 11.2.4. By Drug Class 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Formulation 11.3.3. By Dosage Form 11.3.4. By Drug Class 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. UK. 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Western Europe 12.2.2. By Formulation 12.2.3. By Dosage Form 12.2.4. By Drug Class 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Formulation 12.3.3. By Dosage Form 12.3.4. By Drug Class 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Poland 13.2.1.2. Russia 13.2.1.3. Czech Republic 13.2.1.4. Romania 13.2.1.5. Rest of Eastern Europe 13.2.2. By Formulation 13.2.3. By Dosage Form 13.2.4. By Drug Class 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Formulation 13.3.3. By Dosage Form 13.3.4. By Drug Class 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Bangladesh 14.2.1.3. Australia 14.2.1.4. New Zealand 14.2.1.5. Rest of South Asia and Pacific 14.2.2. By Formulation 14.2.3. By Dosage Form 14.2.4. By Drug Class 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Formulation 14.3.3. By Dosage Form 14.3.4. By Drug Class 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Formulation 15.2.3. By Dosage Form 15.2.4. By Drug Class 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Formulation 15.3.3. By Dosage Form 15.3.4. By Drug Class 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Formulation 16.2.3. By Dosage Form 16.2.4. By Drug Class 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Formulation 16.3.3. By Dosage Form 16.3.4. By Drug Class 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA. 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Formulation 17.1.2.2. By Dosage Form 17.1.2.3. By Drug Class 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Formulation 17.2.2.2. By Dosage Form 17.2.2.3. By Drug Class 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Formulation 17.3.2.2. By Dosage Form 17.3.2.3. By Drug Class 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Formulation 17.4.2.2. By Dosage Form 17.4.2.3. By Drug Class 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Formulation 17.5.2.2. By Dosage Form 17.5.2.3. By Drug Class 17.5.2.4. By Distribution Channel 17.6. UK. 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Formulation 17.6.2.2. By Dosage Form 17.6.2.3. By Drug Class 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Formulation 17.7.2.2. By Dosage Form 17.7.2.3. By Drug Class 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Formulation 17.8.2.2. By Dosage Form 17.8.2.3. By Drug Class 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Formulation 17.9.2.2. By Dosage Form 17.9.2.3. By Drug Class 17.9.2.4. By Distribution Channel 17.10. Poland 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Formulation 17.10.2.2. By Dosage Form 17.10.2.3. By Drug Class 17.10.2.4. By Distribution Channel 17.11. Russia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Formulation 17.11.2.2. By Dosage Form 17.11.2.3. By Drug Class 17.11.2.4. By Distribution Channel 17.12. Czech Republic 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Formulation 17.12.2.2. By Dosage Form 17.12.2.3. By Drug Class 17.12.2.4. By Distribution Channel 17.13. Romania 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Formulation 17.13.2.2. By Dosage Form 17.13.2.3. By Drug Class 17.13.2.4. By Distribution Channel 17.14. India 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Formulation 17.14.2.2. By Dosage Form 17.14.2.3. By Drug Class 17.14.2.4. By Distribution Channel 17.15. Bangladesh 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Formulation 17.15.2.2. By Dosage Form 17.15.2.3. By Drug Class 17.15.2.4. By Distribution Channel 17.16. Australia 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Formulation 17.16.2.2. By Dosage Form 17.16.2.3. By Drug Class 17.16.2.4. By Distribution Channel 17.17. New Zealand 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Formulation 17.17.2.2. By Dosage Form 17.17.2.3. By Drug Class 17.17.2.4. By Distribution Channel 17.18. China 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Formulation 17.18.2.2. By Dosage Form 17.18.2.3. By Drug Class 17.18.2.4. By Distribution Channel 17.19. Japan 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Formulation 17.19.2.2. By Dosage Form 17.19.2.3. By Drug Class 17.19.2.4. By Distribution Channel 17.20. South Korea 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Formulation 17.20.2.2. By Dosage Form 17.20.2.3. By Drug Class 17.20.2.4. By Distribution Channel 17.21. GCC Countries 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Formulation 17.21.2.2. By Dosage Form 17.21.2.3. By Drug Class 17.21.2.4. By Distribution Channel 17.22. South Africa 17.22.1. Pricing Analysis 17.22.2. Market Share Analysis, 2022 17.22.2.1. By Formulation 17.22.2.2. By Dosage Form 17.22.2.3. By Drug Class 17.22.2.4. By Distribution Channel 17.23. Israel 17.23.1. Pricing Analysis 17.23.2. Market Share Analysis, 2022 17.23.2.1. By Formulation 17.23.2.2. By Dosage Form 17.23.2.3. By Drug Class 17.23.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Formulation 18.3.3. By Dosage Form 18.3.4. By Drug Class 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. AstraZeneca plc 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Merck KGaA 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson) 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Galderma SA 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Novartis AG 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. GlaxoSmithKline Plc 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Perrigo Company Plc. 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Cipla Ltd. 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Astellas Pharma Inc. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Takeda Pharmaceutical Company Ltd. 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.11. Eli Lilly and Company 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 19.1.12. Dr. Reddy's Laboratories Ltd. 19.1.12.1. Overview 19.1.12.2. Product Portfolio 19.1.12.3. Profitability by Market Segments 19.1.12.4. Sales Footprint 19.1.12.5. Strategy Overview 19.1.12.5.1. Marketing Strategy 19.1.13. Endo International Inc. 19.1.13.1. Overview 19.1.13.2. Product Portfolio 19.1.13.3. Profitability by Market Segments 19.1.13.4. Sales Footprint 19.1.13.5. Strategy Overview 19.1.13.5.1. Marketing Strategy 19.1.14. Mylan Pharmaceuticals Inc. 19.1.14.1. Overview 19.1.14.2. Product Portfolio 19.1.14.3. Profitability by Market Segments 19.1.14.4. Sales Footprint 19.1.14.5. Strategy Overview 19.1.14.5.1. Marketing Strategy 19.1.15. Teva Pharmaceuticals Ltd. 19.1.15.1. Overview 19.1.15.2. Product Portfolio 19.1.15.3. Profitability by Market Segments 19.1.15.4. Sales Footprint 19.1.15.5. Strategy Overview 19.1.15.5.1. Marketing Strategy 19.1.16. AbbVie (Allergan) 19.1.16.1. Overview 19.1.16.2. Product Portfolio 19.1.16.3. Profitability by Market Segments 19.1.16.4. Sales Footprint 19.1.16.5. Strategy Overview 19.1.16.5.1. Marketing Strategy 19.1.17. GlaxoSmithKline Plc 19.1.17.1. Overview 19.1.17.2. Product Portfolio 19.1.17.3. Profitability by Market Segments 19.1.17.4. Sales Footprint 19.1.17.5. Strategy Overview 19.1.17.5.1. Marketing Strategy 19.1.18. Bayer AG 19.1.18.1. Overview 19.1.18.2. Product Portfolio 19.1.18.3. Profitability by Market Segments 19.1.18.4. Sales Footprint 19.1.18.5. Strategy Overview 19.1.18.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Multiple Unit Pellet Systems Market
